• extension of monitoring of performance indicators to maintenance and supervision of marketing authorisations activities; • support to new topics, such as the ‘common technical document’, within the International Conference in Harmonisation (ICH); • implementation of a quality management system; • development of new tasks in liaison with requests or legislative initiatives of the European Commission (e.g. orphan drugs, herbal remedies, ‘new synthetic drugs’).